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Background: Magnesium plays a key role in maintaining internal homeostasis through actions in the musculoskeletal,
nervous, endocrine and cellular messenger systems. Renal excretion is the major route of magnesium elimination from
the body. A positive magnesium balance would be expected in renal failure. However, a compensatory decrease in
tubular reabsorption is expected to operate to maintain adequate urinary magnesium excretion even when glomerular
filtration rate is very low.
Patients with end-stage renal disease and those on dialysis have impaired regulatory mechanisms, predisposing them
to disturbances in magnesium levels. The effects of high or low magnesium can have deleterious health outcomes,
which impact on the co-morbidities and outcomes of chronic renal disease. This systematic review aims to determine
the prevalence and clinical outcomes of magnesium disorders in end-stage renal disease.
Methods/Design: We will undertake a comprehensive search of various databases, MEDLINE, PubMED, EMBASE,
Cochrane Library, Cochrane Collaboration, CIHNAL (Ebsco), Web of Science and Google Scholar, for observational
studies and clinical trials on magnesium disorders in end-stage renal disease using key terms to identify papers for
inclusion. Paper selection and data extraction (where appropriate) will be performed in duplicate on socio-demographic
characteristics of participants, diagnosis of end-stage renal disease, magnesium levels, prevalence and clinical outcomes.
An assessment of quality will be performed using a modified Newcastle-Ottawa Scale (NOS), including identification
of any bias, which may influence findings. Data will be pooled together according to whether the studies were on
pre-dialysis, hemodialysis or peritoneal dialysis participants. References from individual papers will also be screened
as appropriate. Paper organisation and data extraction and analysis will take place using Microsoft Excel® and Stata
version 13®.
Discussion: This systematic review will represent a significant effort at pooling together information on
prevalence and outcomes of magnesium disturbances amongst end-stage renal disease patients, which may guide
further research and management of the disorders.
Systematic review registration: PROSPERO: CRD42014014354Background
Magnesium is the fourth most abundant cation in the body
and has a role in bone metabolism, cardiovascular function,
neurotransmission and multiple intracellular processes.
Magnesium levels in the body are tightly regulated by a
combination of gastrointestinal and renal mechanisms to
maintain homeostasis. Magnesium is primarily absorbed* Correspondence: John.Floridis@nt.gov.au
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unless otherwise stated.in the proximal small intestine. Excretion occurs via ultra-
filtration of free magnesium through the glomerulus. Once
filtered, a substantial amount may be reabsorbed, predom-
inately in the ascending loop of Henle [1]. Under normal
conditions, both the intake and excretion of magnesium
may be altered to maintain a normal range of total magne-
sium between 0.65 and 0.74 mmol/L [2].
Patients affected by chronic kidney disease (CKD)
experience altered magnesium homeostasis, primarily
through reduced renal excretion, predisposing them to
developing hypermagnesaemia. Whilst there is a lack. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pensate for the reduced ultrafiltration. In patients with
end-stage renal disease who require haemodialysis or
peritoneal dialysis, dialysate fluid contains a variable
amount of magnesium, which may be higher, lower or
equivalent to the target range of normal magnesium
levels [2]. Patients receiving dialysis with low concen-
trations of magnesium may be predisposed to develop-
ing hypomagnesaemia, due to diffusional movements
from the circulation. Additionally, patients with CKD
may be hypomagnesaemic for other reasons, including
the use of proton pump inhibitors, malnutrition or
co-mordities such as alcoholism [3].
Hypomagnesaemia has been observed to increase
cardiovascular risk in patients with chronic kidney dis-
ease [4]. The mechanism is complex, however low mag-
nesium levels facilitate endothelial dysfunction, and
consequently, arterial intimal thickening, arterial calcifi-
cation and oxidative damage, all of which can accelerate
atherosclerosis [5–9]. It is suspected that magnesium
also plays a role in the altered bone metabolism in
chronic renal failure; however, further research is re-
quired to further establish this relationship [2].
This systematic review specifically aims to analyse
evidence on the prevalence of magnesium disturbances
in patients with end-stage renal disease. We aim to pool
together data from observational studies and clinical
trials to assess trends in magnesium levels and effects on
outcomes such as cardiovascular co-morbidities, for
example, ischaemic heart disease, vascular calcification,




The methods and design of this systematic review are
based on recommendations from the Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA-P)
statements and the Meta-analysis of Observational Studies
in Epidemiology (MOOSE) [10, 11]. PRISMA requires a
description of the eligibility criteria using the PICOS (the
participants, interventions, comparisons, outcome(s) and
study design of the systematic review) reporting system.
This review will include observational studies and clinical
trials, hence we will use both the PICOS and, in accord-
ance with the MOOSE guidelines, the eligibility criteria by
means of the participants/population, exposure(s), com-
parator(s)/control, outcome(s) and study design (PECOS).
The patient population are patients with end-stage renal
disease and those on haemodialysis or peritoneal dialysis.
The exposures will be any factors, which we feel may
impact serum magnesium levels, including, but not lim-
ited to, dialysate concentration, co-morbidities, concur-
rent proton pump inhibitor use and use of magnesiumsupplementation. Outcomes will be serum magnesium
levels, in addition to mortality (adjusted for con-
founders), and impact on associated co-morbidities, for
example, glycaemic control or dyslipidaemia. The
protocol is registered with the International Prospective
Register of Systematic Reviews (Registration Number:
CRD42014014354).
Objectives
The aim of this systematic review is to assess the preva-
lence of magnesium disorders in patients with end-stage
renal disease: pre-dialysis, and those on peritoneal dialy-
sis and haemodialysis. Furthermore, we hope to assess
the associated impact on outcomes such as cardiovascu-
lar disease and other outcomes.
Inclusion and exclusion criteria
The population of interest will be all patients with
end-stage renal disease, pre-dialysis and those requiring
regular haemodialysis or peritoneal dialysis. Cross-sectional,
cohort, clinical trials, case–control and observational
studies will be included. Individual case reports will be
excluded. Studies may arise from any geographical or
socioeconomic location but must be published in English.
Study selection
Studies assessing prevalence of magnesium disorders and
outcomes in end-stage renal disease will be selected. Search
results will be imported and stored into Endnote software.
Two reviewers will independently screen titles and abstracts
for relevance and consideration into a provisional list. Indi-
vidual lists of articles will then be assessed independently
by each reviewer for potential inclusion.
After a defined time period, the two reviewers will
meet and reach a consensus about which articles are to be
included. A third party investigator will discuss any dis-
agreement until a consensus is reached. Upon completion,
a flowchart will be prepared, as outlined in Additional
file 1, which will include numerical values of accepted
and rejected studies throughout this process.
Search strategy
We will conduct the search by formulating a database
containing published studies in peer-reviewed journals,
addressing the prevalence and outcomes of magnesium
disorders in end-stage renal disease patients. A systematic
search of MEDLINE via Ovid, PubMED, Excerpta Medica
Database (EMBASE), Cochrane Library, Cochrane Col-
laboration, Cochrane Database of Systematic Reviews
(CDSR), Nursing and Allied Health Literature (CIHNAL)
(Ebsco), Web of Science and Google Scholar will be
undertaken. We will examine publications from 1966 until
2014. Search terms will include controlled vocabulary
and text-words. Terms to be searched in isolation and
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“magnesium disorders”, “hypomagnesaemia”, “hypermag-
nesaemia”, “magnesium disturbance”, “magnesium”, “mor-
tality”, “all cause mortality”, “cardiovascular mortality”, “all
cause mortality”, “survival”, “long term survival”, “carotid
intima media thickness”, “vascular calcification”, “renal
disease”, “chronic kidney disease”, “end-stage renal dis-
ease”, “dialysis”, “peritoneal dialysis”, “haemodialysis”, “car-
diovascular”, “ischaemic heart disease”, “vascular disease”,
“diabetes”, “hypertension” and “hypercholesterolaemia”.
Terms will be expanded to take into account spelling dif-
ferences of keywords between different countries and jour-
nals. See Additional file 2 for more details, which
summarises the search terms for MEDLINE.
The search will be performed in close cooperation
with an experienced librarian. Articles for selection must
be peer reviewed, full text and written in English. Refer-
ence lists of individual papers will also be reviewed
where appropriate and relevant to the clinical question.
Data extraction
Papers and any appropriate data will be categorised and
standardised using Microsoft Excel® and Stata version
13®. One reviewer will categorise papers, extract and in-
put any relevant data from the final list of studies, whilst
the second reviewer will validate data. The following
data will be extracted:
1. Publication details
2. Study design
3. Study participant details (baseline characteristics)
4. Stage of end-stage renal disease: pre-dialysis, haemo-
dialysis or peritoneal dialysis
5. Co-morbidities
6. Use of proton pump inhibitors
7. Composition of dialysate fluid, specifically
magnesium and calcium concentration
8. Data for outcome measures: serum magnesium
levels
9. Data for additional clinical outcome measures,
including, but not limited to glycaemic control, lipid
profiles, blood pressure, or arterial calcification
10. Limitations including any bias which affect quality
of the paper
Quality assessment
Two reviewers, using a standardised approach, will inde-
pendently assess the quality of papers. This process will
follow the initial selection of papers as outlined previously.
Any discrepancies will be resolved by discussion, including
a third reviewer where consensus is not reached.
To increase the robustness of the quality assessment
for this review, we will use the Newcastle-Ottawa Scale
(NOS) for the quality assessment of non-randomisedstudies. [12]. We will modify it for clarity of scoring the
studies for quality [13]. The risk of bias will be inde-
pendently assessed by two reviewers for each of the
included studies using the modified NOS, specific to the
context of this review. This will include seven questions
spread across four domains for evaluating: methods for
selecting study participants (selection bias), methods to
control for confounding factors (performance bias), stat-
istical methods (detection bias) and methods for measur-
ing exposure and outcome variables (information bias).
Risk of bias is measured on a scale of 0 (high risk of
bias) to 3 (low risk of bias). A specific description with
examples of both high and low bias is provided in
Additional file 3. In the modification of the NOS, items
regarding selection of participants (representativeness of
sample) and ascertainment of outcome (objective versus
subjective measures) were retained, whilst other items
relating to the comparability of groups and adequate
follow-up for cohort and case–control studies were
removed as these are not directly applicable to current
review. Categories that emphasise statistical methods,
confounding effects and reporting of data to ensure that
bias in methodology are minimised will be assessed.
These scales will be used to measure the risk of bias on
a per study basis or categorized by domain to develop a
general conclusion about the sources of bias in the studies
included in this review [13]. Quality scores will be pre-
sented in a table. An additional file shows this in more
detail [see Additional file 4].
Data synthesis
The number of papers included and excluded during
the systematic review process will be clearly presented
in a flowchart for clear transparency, as outlined in
Additional file 1. It is anticipated that there will be het-
erogeneity amongst papers reviewed, in their design and
dataset. Evidence tables will be used to summarise rele-
vant data extracted from eligible studies. However, pa-
pers selected will be presented in summary table for
clear interpretation and application to the systematic re-
view. Subgrouping of data will be performed by end-
stage renal disease status (pre-dialysis, peritoneal dialy-
sis or haemodialysis). A summary of the prevalence of
magnesium disorders will be provided in a narrative
synthesis according to patient details, stage of chronic
kidney disease, dialysis modalities, and co-morbidities
as well as the predictors of magnesium disorders wher-
ever possible. Limitations of the studies will be dis-
cussed in detail. In observational papers, the main
outcome of interest will be presented, based on the na-
ture of the study.
The review will also comprise subgroup analysis by
end-stage renal disease status and draw upon any associ-
ations between variables.
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Magnesium disorders in people with end-stage renal dis-
ease may be more common than is currently known. It
is not clear in many guidelines whether treatment to
correct magnesium disorders is warranted. The strength
of this review is that it will to clearly establish the preva-
lence of magnesium disorders in ESRD patients. Whilst
previous literature has highlighted the concerns around
magnesium disturbances in this population, results are
variable with many associations in place, based on indir-
ect in vitro and in vivo studies. Furthermore, whilst
hypomagnesaemia has been acknowledged as a concern
due to impact on clinical outcomes, there is still no con-
sensus about how to manage this electrolyte imbalance
in clinical practice—with or without magnesium supple-
mentation in people with ESRD.
Limitations
Study inclusion will involve judgements from both re-
viewers. Whilst this process will be undertaken inde-
pendently to minimise bias, we acknowledge that, where
duplication of studies exist, author bias can still occur.
Dissemination
The results of the systematic review will be published in
peer-reviewed journals and presented at conferences
where appropriate.
Additional files
Additional file 1: Flow chart to summarise the search strategy.
The flowchart illustrates the proposed method of systematically reviewing
literature, which will include numerical values upon completion.
Additional file 2: Search strategy—MEDLINE via Ovid. The search
strategy outlines the keywords, which will be used in MEDLINE via Ovid,
however a homogenous approach will be incorporated in other search
engines to ensure all relevant literature is captured as part of the review.
Additional file 3: Modified Newcastle-Ottawa Scale (NOS) For
Quality Assessment of the Studies Included in the Systematic Review.
The modified NOS will be applied to all literature reviewed to assess for
quality. Complete scores will be available in the completed systematic
review, which allow conclusions from various studies to be weighted
accordingly.
Additional file 4: Proposed table of studies reviewed, incorporating
modified NOS assessment. This table will be the proposed format in
which the studies are listed in the systematic review to allow for a clear
and concise presentation of the relevant literature.
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